KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Free Cash Flow (2018 - 2025)

Esperion Therapeutics' Free Cash Flow history spans 8 years, with the latest figure at $45.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 229.44% year-over-year to $45.2 million; the TTM value through Dec 2025 reached -$13.1 million, up 45.38%, while the annual FY2025 figure was -$13.1 million, 45.38% up from the prior year.
  • Free Cash Flow reached $45.2 million in Q4 2025 per ESPR's latest filing, up from -$4.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $53.8 million in Q1 2024 to a low of -$89.1 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$30.6 million, with a median of -$36.3 million recorded in 2023.
  • The largest YoY upside for Free Cash Flow was 229.44% in 2025 against a maximum downside of 331.5% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$57.7 million in 2021, then rose by 26.4% to -$42.5 million in 2022, then grew by 12.75% to -$37.1 million in 2023, then rose by 5.68% to -$35.0 million in 2024, then skyrocketed by 229.44% to $45.2 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Free Cash Flow are $45.2 million (Q4 2025), -$4.3 million (Q3 2025), and -$31.4 million (Q2 2025).